LIFR and neoplasm: Moreover, rational combination strategies, including LIFR inhibition with immune checkpoint blockade (e.g., anti–PD‐1/PD‐L1) or TAM reprogramming agents, may yield synergistic anti‐tumor effects, particularly in “cold” tumors with poor CD8+ T‐cell infiltration.